Infection risk remains a prominent clinical concern for patients with multiple myeloma (MM), even with the advent of modern, ...

Bispecific antibody therapy is transforming cancer treatment, especially in multiple myeloma, with ongoing studies exploring ...

On the basis of the data presented from the MM-009 and MM-010 trials, FDA approved lenalidomide for use in combination with dexamethasone in patients with MM who have received one prior therapy ...

They report a concerning relationship between micro and nanoplastic (MNP) concentrations in damaged tissues and links with multiple health ... particles detected in skin, arteries, veins, thrombi ...

The MRC Myeloma IX trialists defined high-risk disease by the presence of multiple adverse FISH lesions combined with ISS II or III. In the Intergroupe Francophone du Myélome experience ...